266 related articles for article (PubMed ID: 36621810)
1. Cancer Therapy-Related Hypertension: A Scientific Statement From the American Heart Association.
Cohen JB; Brown NJ; Brown SA; Dent S; van Dorst DCH; Herrmann SM; Lang NN; Oudit GY; Touyz RM;
Hypertension; 2023 Mar; 80(3):e46-e57. PubMed ID: 36621810
[TBL] [Abstract][Full Text] [Related]
2. VEGF Receptor Inhibitor-Induced Hypertension: Emerging Mechanisms and Clinical Implications.
Camarda N; Travers R; Yang VK; London C; Jaffe IZ
Curr Oncol Rep; 2022 Apr; 24(4):463-474. PubMed ID: 35179707
[TBL] [Abstract][Full Text] [Related]
3. Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors.
Dobbin SJH; Cameron AC; Petrie MC; Jones RJ; Touyz RM; Lang NN
Heart; 2018 Dec; 104(24):1995-2002. PubMed ID: 30228246
[TBL] [Abstract][Full Text] [Related]
4. Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome.
Small HY; Montezano AC; Rios FJ; Savoia C; Touyz RM
Can J Cardiol; 2014 May; 30(5):534-43. PubMed ID: 24786444
[TBL] [Abstract][Full Text] [Related]
5. Hypertension and Prohypertensive Antineoplastic Therapies in Cancer Patients.
van Dorst DCH; Dobbin SJH; Neves KB; Herrmann J; Herrmann SM; Versmissen J; Mathijssen RHJ; Danser AHJ; Lang NN
Circ Res; 2021 Apr; 128(7):1040-1061. PubMed ID: 33793337
[TBL] [Abstract][Full Text] [Related]
6. Vascular Complications of Cancer Chemotherapy.
Cameron AC; Touyz RM; Lang NN
Can J Cardiol; 2016 Jul; 32(7):852-62. PubMed ID: 26968393
[TBL] [Abstract][Full Text] [Related]
7. Team-Based Approach to Management of Hypertension Associated with Angiogenesis Inhibitors.
Patel S; Dushenkov A; Jungsuwadee P; Krishnaswami A; Barac A
J Cardiovasc Transl Res; 2020 Jun; 13(3):463-477. PubMed ID: 32430701
[TBL] [Abstract][Full Text] [Related]
8. Vascular toxicity associated with anti-angiogenic drugs.
Neves KB; Montezano AC; Lang NN; Touyz RM
Clin Sci (Lond); 2020 Sep; 134(18):2503-2520. PubMed ID: 32990313
[TBL] [Abstract][Full Text] [Related]
9. [Vascular and renal effects of anti-angiogenic therapy].
Halimi JM; Azizi M; Bobrie G; Bouché O; Deray G; des Guetz G; Lecomte T; Levy B; Mourad JJ; Nochy D; Oudard S; Rieu P; Sahali D
Nephrol Ther; 2008 Dec; 4(7):602-15. PubMed ID: 19027389
[TBL] [Abstract][Full Text] [Related]
10. Molecular basis of hypertension side effects induced by sunitinib.
Aparicio-Gallego G; Afonso-Afonso FJ; León-Mateos L; Fírvida-Pérez JL; Vázquez-Estévez S; Lázaro-Quintela M; Ramos-Vázquez M; Fernández-Calvo O; Campos-Balea B; Antón-Aparicio LM
Anticancer Drugs; 2011 Jan; 22(1):1-8. PubMed ID: 20938340
[TBL] [Abstract][Full Text] [Related]
11. Microparticles from vascular endothelial growth factor pathway inhibitor-treated cancer patients mediate endothelial cell injury.
Neves KB; Rios FJ; Jones R; Evans TRJ; Montezano AC; Touyz RM
Cardiovasc Res; 2019 Apr; 115(5):978-988. PubMed ID: 30753341
[TBL] [Abstract][Full Text] [Related]
12. VEGF (Vascular Endothelial Growth Factor) Inhibition and Hypertension: Does Microvascular Rarefaction Play a Role?
le Noble FAC; Mourad JJ; Levy BI; Struijker-Boudier HAJ
Hypertension; 2023 May; 80(5):901-911. PubMed ID: 36748474
[TBL] [Abstract][Full Text] [Related]
13. Arterial hypertension in patients under antineoplastic therapy: a systematic review.
Katsi V; Magkas N; Georgiopoulos G; Athanasiadi E; Virdis A; Masi S; Kliridis P; Hatziyanni A; Tsioufis C; Tousoulis D
J Hypertens; 2019 May; 37(5):884-901. PubMed ID: 30624368
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor inhibitor-induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors.
Kruzliak P; Novák J; Novák M
Am J Hypertens; 2014 Jan; 27(1):3-13. PubMed ID: 24168915
[TBL] [Abstract][Full Text] [Related]
15. Use of Antihypertensive Drugs in Neoplastic Patients.
Rizzoni D; De Ciuceis C; Porteri E; Agabiti-Rosei C; Agabiti-Rosei E
High Blood Press Cardiovasc Prev; 2017 Jun; 24(2):127-132. PubMed ID: 28361339
[TBL] [Abstract][Full Text] [Related]
16. Vascular Cardio-Oncology: Vascular Endothelial Growth Factor inhibitors and hypertension.
Versmissen J; Mirabito Colafella KM; Koolen SLW; Danser AHJ
Cardiovasc Res; 2019 Apr; 115(5):904-914. PubMed ID: 30726882
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer.
Chuai Y; Rizzuto I; Zhang X; Li Y; Dai G; Otter SJ; Bharathan R; Stewart A; Wang A
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013348. PubMed ID: 33661538
[TBL] [Abstract][Full Text] [Related]
18. Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors.
Maurea N; Coppola C; Piscopo G; Galletta F; Riccio G; Esposito E; De Lorenzo C; De Laurentiis M; Spallarossa P; Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e19-e26. PubMed ID: 27755239
[TBL] [Abstract][Full Text] [Related]
19. The emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitors.
Tocchetti CG; Gallucci G; Coppola C; Piscopo G; Cipresso C; Maurea C; Giudice A; Iaffaioli RV; Arra C; Maurea N
Eur J Heart Fail; 2013 May; 15(5):482-9. PubMed ID: 23325019
[TBL] [Abstract][Full Text] [Related]
20. The emerging role of vascular endothelial growth factor (VEGF) in vascular homeostasis: lessons from recent trials with anti-VEGF drugs.
Thanigaimani S; Kichenadasse G; Mangoni AA
Curr Vasc Pharmacol; 2011 May; 9(3):358-80. PubMed ID: 20807189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
